Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...
Since 2019, Cytiva has committed over $1.6 billion to expand its global manufacturing capacity. In this exclusive conversation with BioPharma BoardRoom, Pi...
First patient received bilateral administration of NRTX-1001; no significant surgical complications or adverse events reported to date - - Trial funded...
Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric disorders with a rich pipeline of ...
Investment supports the development of first-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existi...
SynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the drug could halt disease progression and even rever...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifescienc...
Financing led by Novo Holdings with significant support from world-class group of existing and new investors Proceeds from financing to support developm...
Brain Cancer Canada is pleased to award $68,000 for an innovative research initiative led by Dr. Aru Narendran, MD, PhD, and Dr. Patrick Sipila, PhD, at ...
Angelini Ventures joins top-tier investor syndicate Investment will fund Phase 1b studies evaluating Therini Bio’s lead candidate, THN391, for ...
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, toda...
Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $...
Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into ...
Roche announced that it will invest USD 50 billion into the United States of America in the next five years. These investments further strength...
© 2025 Biopharma Boardroom. All Rights Reserved.
